Abstract
Biomedical research cannot succeed without funding, knowledgeable staff, and appropriate infrastructure. There are however equally important but intangible factors that are rarely considered in planning large multidisciplinary endeavors or evaluating their success. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial required extensive collaborations between individuals from many fields, including clinicians, clinical trialists, and administrators; it also addressed questions across the spectrum of cancer prevention and control. In this manuscript, we examine the experiences and opinions of trial staff regarding the building of successful relationships in PLCO. We summarize, in narrative form, data collected using open-ended questionnaires that were administered to the National Cancer Institute project officers, coordinating center staff, screening center principal investigators, and screening center coordinators in 2015, about 3 years after publication of the final primary trial manuscript. Trust, respect, listening to others, and in-person interaction were frequently mentioned as crucial to building successful relationships.
Keywords: Cancer screening, collaboration, multidisciplinary, PLCO, randomized controlled trials as subject, team science.
Reviews on Recent Clinical Trials
Title:Building Successful Relationships in the PLCO Cancer Screening Trial
Volume: 10 Issue: 3
Author(s): Victoria Jenkins, Susan Yurgalevitch, Lance A. Yokochi, Vicki Shambaugh, Douglas Reding, Philip C. Prorok, Sheryl L. Ogden, Barbara O’Brien, Karen Lappe, Christine C. Johnson, Pamela M. Marcus, Rachel Jaggi, Darlene Higgins, Lisa H. Gren, John K. Gohagan, Timothy R. Church, Jeffery Childs, Saundra S. Buys and Karen G. Broski
Affiliation:
Keywords: Cancer screening, collaboration, multidisciplinary, PLCO, randomized controlled trials as subject, team science.
Abstract: Biomedical research cannot succeed without funding, knowledgeable staff, and appropriate infrastructure. There are however equally important but intangible factors that are rarely considered in planning large multidisciplinary endeavors or evaluating their success. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial required extensive collaborations between individuals from many fields, including clinicians, clinical trialists, and administrators; it also addressed questions across the spectrum of cancer prevention and control. In this manuscript, we examine the experiences and opinions of trial staff regarding the building of successful relationships in PLCO. We summarize, in narrative form, data collected using open-ended questionnaires that were administered to the National Cancer Institute project officers, coordinating center staff, screening center principal investigators, and screening center coordinators in 2015, about 3 years after publication of the final primary trial manuscript. Trust, respect, listening to others, and in-person interaction were frequently mentioned as crucial to building successful relationships.
Export Options
About this article
Cite this article as:
Jenkins Victoria, Yurgalevitch Susan, A. Yokochi Lance, Shambaugh Vicki, Reding Douglas, C. Prorok Philip, L. Ogden Sheryl, O’Brien Barbara, Lappe Karen, C. Johnson Christine, M. Marcus Pamela, Jaggi Rachel, Higgins Darlene, H. Gren Lisa, K. Gohagan John, R. Church Timothy, Childs Jeffery, S. Buys Saundra and G. Broski Karen, Building Successful Relationships in the PLCO Cancer Screening Trial, Reviews on Recent Clinical Trials 2015; 10 (3) . https://dx.doi.org/10.2174/1574887110666150731131743
DOI https://dx.doi.org/10.2174/1574887110666150731131743 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Systems Biology Approaches to a Rational Drug Discovery Paradigm
Current Topics in Medicinal Chemistry Synthesis and Biological Evaluation of Estradiol-Core Derivatives Bearing a Fused γ-Lactone as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1
Current Enzyme Inhibition Gene Delivery for Cancer Therapy
Current Drug Delivery Synthesis and In Vitro Cytotoxic Activity Evaluation of Novel Mannich Bases and Modified AZT Derivatives Possessing Mannich Base Moieties via Click Chemistry
Letters in Drug Design & Discovery Antisense Treatment in Human Prostate Cancer and Melanoma
Current Cancer Drug Targets Immune Responses to Fungal Infections and Therapeutic Implications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Vascular Disrupting Agents (VDAs) in Anticancer Therapy
Current Clinical Pharmacology How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy
Anti-Cancer Agents in Medicinal Chemistry The Contribution of Transcriptomics to Biomarker Development in Systemic Vasculitis and SLE
Current Pharmaceutical Design Development of Taxol and Other Endophyte Produced Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery Effects of PPARγ Ligands on Vascular Tone
Current Molecular Pharmacology Advances and Patents about Grinding Equipments with Nano-Particle Jet Minimum Quantity Lubrication
Recent Patents on Nanotechnology Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design Cisplatin Cytotoxicity: DNA and Plasma Membrane Targets
Current Medicinal Chemistry Thioredoxin Reductase and its Inhibitors
Current Protein & Peptide Science High Podophyllotoxin Producing Hairy Root Line of Linum Album: Influence of Carbohydrates, Temperature and Photoperiod
Current Biotechnology Melatonin: Pharmacology, Functions and Therapeutic Benefits
Current Neuropharmacology Prostate Cancer Molecular Background: The IGF-1Ec Story
Clinical Cancer Drugs Design, Synthesis and Multidrug Resistance Reversal Activity Evaluation of 8-Oxocoptisine Derivatives
Medicinal Chemistry Enhancing the Therapeutic Efficacy of Bortezomib in Cancer Therapy Using Polymeric Nanostructures
Current Pharmaceutical Design